4.0
17 Apr 2023
Former employee, more than 3 years
Taipei
Recommend
CEO approval
Business outlook
Pros
Company really dedicated to make effort on increasing patient access, as well as biosimilar education.
Cons
Generic market is more focus on price competition, medical affairs played a supportive role. Recent years of transition create instability for employees.